CD4 and breast carcinoma: For example, the checkpoint gene PD-L1 is regulated by NR4A1 in breast cancer cells and treatment with CDIM/NR4A1 antagonists decreased PD-L1 and enhanced immune surveillance (increased CD8 + /CD4 + ratios) in syngeneic mouse breast cancer model [23].